NCT07230483 A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
| NCT ID | NCT07230483 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Keymed Biosciences Co.Ltd |
| Condition | Atopic Dermatitis (AD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 246 participants |
| Start Date | 2025-12 |
| Primary Completion | 2027-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 246 participants in total. It began in 2025-12 with a primary completion date of 2027-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.
Eligibility Criteria
Inclusion Criteria: * Have the ability to understand the study and voluntarily sign a written informed consent form (ICF). * Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001. Exclusion Criteria: * Not enough washing-out period for previous therapy. * Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
Contact & Investigator
Jianzhong Zhang
PRINCIPAL INVESTIGATOR
Peking University People's Hospital
Frequently Asked Questions
Who can join the NCT07230483 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atopic Dermatitis (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07230483 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07230483 currently recruiting?
Yes, NCT07230483 is actively recruiting participants. Contact the research team at qianjia@keymedbio.com for enrollment information.
Where is the NCT07230483 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07230483 clinical trial?
NCT07230483 is sponsored by Keymed Biosciences Co.Ltd. The principal investigator is Jianzhong Zhang at Peking University People's Hospital. The trial plans to enroll 246 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.